Preclinical studies report approximately 1.6 increases in intracellular NAD+ following NNMT inhibition in adipocyte models
Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Supports peak mental and physical functions
[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Breitinger U., Zakaria Z.I.S., Mahgoub H.A., Wiessler A.L., Tuerker E., Villmann C., Breitinger H.G
Frequently Asked Questions Glossary References Petrovic I, et al